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The 5D Framework: A Clinical Primer for Fecal Microbiota Transplantation to Treat Clostridium 
difficile infection  
 
 
 
Clostridium difficile infection (CDI) is the most common health care-associated infection in the 
United States. Recently, fecal microbiota transplantation (FMT) has emerged as an effective and 
safe therapy for recurrent CDI; however, despite rapid adoption there is no standardized clinical 
approach.  Given the rapid adoption of FMT, in part due to stool banks, there is a need for a 
practical primer for clinicians to safely perform FMT. Accordingly, we aim to provide a simple 
approach entitled the 5D FMT framework to guide physicians. The 5D FMT framework includes: 
Decision (selecting appropriate patient for FMT), Donor (selection and screening), Discussion 
(risk, benefits, alternatives), Delivery (selecting appropriate modality for FMT administration) , 
and Discharge (counseling at discharge and follow-up). We aim to help clinicians take a simple 
but evidence-based approach to FMT to optimize efficacy and safety. This primer navigates how 
to decide if a CDI patient is appropriate for FMT, select and screen stool donors, identify the 
ideal delivery modality and provide follow-up care after FMT. 
 
 
Introduction 
 
Clostridium difficile infection (CDI) is a significant public health risk and has emerged as the most 
common cause of health-care associated infection in the United States.
 1, 2
 The rise of CDI is a 
reflection, in part, of challenges with antibiotic stewardship and the emergence of more virulent 
strains.
 3
 Epidemiologic data suggest CDI-associated hospitalizations nearly doubled from 2000 
to 2010
 4-6
 and a recent study estimated 29,300 annual CDI-associated deaths in the United 
States.
 2
   
 
Fecal microbiota transplantation (FMT) is now regarded as a safe and effective therapy for the 
treatment of recurrent CDI. Although the mechanism of action for FMT has not been fully 
elucidated, there is speculation that it establishes a newly enriched microbiota that directly and 
indirectly inhibits C difficile by production of bactericidal proteins (bacteriocins) as well as 
competing for nutritional and colonization resources. 7-10 The mechanism of FMT expands 
beyond the changes in the microbial community structure to include restoration of microbial 
functionality.
 11
 Specifically, FMT reestablishes normal microbial communities involved in 
secondary bile acid metabolism, a process disrupted by antibiotics, and further suppressed in 
recurrent CDI.
 12
 Data suggested a number of bacteria with known bile salt hydrolase activity are 
found to be present at higher levels post-FMT compared to pre-FMT including Bacteroides 
ovatus, Bacteroides vulgatus, Blautia obeum, Collinsella aerofaciens, Dorea longicatena, 
Eubacterium rectale, Faecalibacterium prausnitzii, Parabacteroides distasonis, and 
Ruminococcus torquesrectale
 13
. Overall, restoration of secondary bile acid dominance in the 
colon appears to create an inhibitory milleu for C difficile spore germination and vegetative 
growth.
 14, 15
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To date, four randomized controlled trials have measured the efficacy of FMT compared to 
standard therapies and, more recently, compared to placebo.
 16-19
 Van Nood and colleagues 
conducted a three-arm, open-label randomized controlled trial comparing FMT by naso-
duodenal tube after an abbreviated course of vancomycin and bowel lavage, standard oral 
vancomycin and oral vancomycin plus standard bowel lavage. The study was halted early due to 
the superior effectiveness of the FMT arm.
 18
 More recently, Kelly and colleagues
17
 were the first 
to conduct a placebo-controlled study and reported an overall 90.9% efficacy rate in the FMT 
arm compared to 62.5% in the placebo arm (autologous FMT).
 
 Several systematic reviews and 
meta-analyses have shown efficacy rates ranging from 80% to 90% for treating recurrent CDI 
with a single FMT infusion.
 16, 20-22
 
 
From a safety perspective, aside from mild, transient adverse events such as abdominal pain, 
which may be driven by the delivery modality, FMT is well tolerated with a favorable short-term 
safety profile. However, recent systematic reviews and meta-analyses, suggested more adverse 
events with the upper gastrointestinal (GI) delivery route (eg, naso-enteric tube) compared with 
lower GI administration (eg, colonoscopy, enema).
 23
 There is a paucity of data regarding the 
long-term safety of FMT. Although there is no evidence thus far, there are theoretical concerns 
that microbiota acquired from donor stool could increase the risk of potentially microbiome-
mediated diseases. Ongoing studies including the STOOL study (Clinicaltrials.gov NCT02403622) 
and a national FMT registry recently funded by the National Institutes of Health, which will 
prospectively monitor 4,000 patients for up to 10 years post-FMT, will help determine the short 
and long-term safety profile of FMT. 
 
In terms of regulation of FMT, the U.S. Food and Drug Administration (FDA) issued a public 
announcement in May 2013 stating that it would regulate FMT and fecal material as both a drug 
and a biologic product.
 24
 Practically, this would have required clinicians to submit an 
Investigational New Drug (IND) application before performing FMT to provide oversight, 
standardization, and increased safety. However, clinicians, patients, and stakeholders voiced 
concern that the IND requirement would limit access to the procedure and catalyze risky, 
unscreened “do-it- yourself FMT.” Accordingly, the Agency revised its position and announced 
that it would not enforce the IND requirement for the treatment of C difficile infections not 
responsive to standard therapies.
 25
This enforcement discretion does not apply to indications 
other than CDI, which still require an IND.
 26
 
 
Given the rapid adoption of FMT, in part due to stool banks, there is a need for a practical 
primer for clinicians to safely perform FMT.
 27
 Accordingly, we aim to provide a simple approach 
entitled the 5D FMT framework to guide physicians. The 5D FMT framework includes: Decision, 
Donor, Discussion, Delivery, and Discharge (Table 1).  
 
(1) Decision: Deciding on the appropriate CDI patient to undergo FMT 
 
Indications for FMT  
The initial FMT working group, consisting of gastroenterology and infectious disease thought 
leaders, recommended, the primary indications for FMT are as follows: (1) Recurrent CDI 
defined as 3 or more episodes of mild to moderate CDI and failure to respond to a 6- to 8-week 
taper of vancomycin or at least 2 episodes of CDI requiring hospitalization and associated with 
significant morbidity; (2) Moderate CDI with no response to standard therapy for at least one 
week and (3) Severe CDI with no response to standard therapy for 48 hours. 28, 29However many 
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of the RCTs that came out after these initial recommendations enrolled patients who had failed 
an initial course of antibiotics.
 18
 The American College of Gastroenterology and European 
Society of Clinical Microbiology and Infectious Diseases have both included FMT as an option for 
recurrent CDI in published treatment guidelines. 
 7, 30
 The recent European FMT guidelines report 
a strong recommendation with high quality of evidence for the use of FMT for the treatment of 
recurrent CDI with overall resolution rates ranging between 85% to 89.7%. The recommendation 
for refractory CDI is also strong although the quality of evidence is low; however, it is noted that 
patients with refractory CDI likely have more severe disease. The guidelines do not recommend 
the use of FMT for the first episode CDI, given insufficient evidence.
 30
 
 
In terms of severe CDI, there is emerging evidence to suggest that FMT may be a useful tool in 
the treatment of severe or severe-complicated CDI. Although colectomy remains the standard of 
care for fulminant cases, it carries significant morbidity with operative mortality rates 
approaching 50%.
 31
 There have been several reports on the use of FMT in this population, and 
the data is promising.
 32, 33
 Fischer et al presented a series of 57 patients, refractory to maximal 
medical therapy, who received an FMT in combination with selective use of vancomycin.
 34
 The 
sequential FMT protocol consisted of at least one FMT delivered via colonoscopy, with criteria 
for continued vancomycin based on the presence of pseudomembranes on endoscopic 
evaluation and criteria to determine the need for repeat FMT based on clinical response. Among 
the patients treated with this sequential FMT protocol, 91% (52/57) experienced clinical cure at 
1 month with a 100% cure rate for severe CDI (n = 19) and an 87% cure rate for severe-
complicated CDI (n = 33).
 34
 This emerging body of literature on the use of FMT in critically ill 
patients may suggest it may be a viable alternative to colectomy; however, randomized 
controlled trials are needed.  
 
CDI Stool Testing 
Before performing a FMT clinicians should review all available CDI tests, including the type and 
timing, performed on the patient in order to confirm the diagnosis. Clinicians should carefully 
review if a nucleic acid amplification test (NAATs also called PCR) for the C difficile toxin gene or 
a toxin A/B enzyme immunoassay (EIA) that directly detects C difficile toxin was conducted. If 
only NAAT/PCR testing is available, eliciting a history of clinical response to anti-CDI antibiotics is 
important to distinguishing true infection from colonization, as presence of a C difficile toxin 
gene does not mean toxin is being produced. If patients do not respond to anti-CDI antibiotics 
and have ongoing or intermittent diarrhea, other etiologies should be investigated.  
 
We would recommend clinicians follow the 2016 European Society of Clinical Microbiology and 
Infectious Diseases (ESCMID) guidelines for CDI testing, which state that no single commercial 
test can be used as a stand-alone test for diagnosing CDI, and recommend a 2-step approach 
(highly sensitive with reflex to highly specific test).
 35
 These guidelines recommend performing 
an initial test with a high negative predicative value; therefore, if negative, no further testing 
needs to be done. Specifically, they suggest glutamate dehydrogenase (GDH) EIA or NAAT/PCR 
testing. Our recommendation is GDH EIA as it is less expensive and has a slightly superior NPV at 
higher CDI prevalence compared with NAAT/PCR (98 vs 96 at hypothetical CDI prevalence of 
50%), and an NPV of 100% at lower CDI prevalence. 35 The second test should be a test with a 
high positive predictive value, such as EIA for toxin A/B. Obtaining CDI testing at each suspected 
CDI recurrence and working with institutional laboratories to use an appropriate testing 
algorithm is a key component to ensuring appropriate patient selection for FMT. Overall, a 
clinician’s understanding of CDI testing is crucial given the high sensitivity of stool NAAT/PCR 
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testing and the frequency of colonization, especially in elderly or hospitalized patients, on the 
background of other conditions (eg, post-infectious irritable bowel syndrome) presenting with 
diarrheal symptoms, which can result in a misdiagnosis of CDI. This concept is highlighted by 
evidence suggesting that up to 25% of patients referred to an FMT center for “C difficile 
infection” were found to have an alternative diagnosis, with younger patients being more likely 
to have a non-CDI diagnosis.
 36
 Overall, clinicians should consider other possible etiologies for 
diarrheal symptoms including post-infectious irritable bowel syndrome, inflammatory bowel 
disease, microscopic colitis, bile salt diarrhea, celiac disease, chronic pancreatitis, other 
infectious etiologies, or factitious diarrhea.  
 
Special populations     
Specific exclusions may be based on the modality of delivery considered and will be discussed 
further below. Other populations in which FMT should not be offered include patients who are 
neutropenic. Additionally, there is limited data on pregnant patients, therefore would not 
recommend FMT given the current body of evidence.
 37
 The patient who will require long-term 
chronic antibiotics should be considered carefully, given the disruption of the healthy 
microbiota instilled, and the increased likelihood of FMT failure, although this is not an absolute 
contraindication. Finally, FMT may not be ideal in patients with limited life expectancy, such as 
those with advanced malignancy, in whom it may be more suitable to treat with low dose 
vancomycin to prevent CDI recurrence rather than subjecting them to an invasive procedure. 
However, CDI may be debilitating and given the focus of quality of life in this population, the 
decision to proceed or not with FMT should be made on a case-by-case basis in the context of 
patient goals of care. Overall, clinicians must be thoughtful in the decision to offer a patient with 
CDI an FMT.  
 
Patients with inflammatory bowel disease (IBD) and CDI represent a unique and challenging 
population. Kelly and colleagues demonstrated that FMT is safe in patients who are 
immunosuppressed and this included patients with IBD on various IBD therapies
 38
. 
Consideration should be given to IBD disease activity in these patients. Colonoscopic 
administration may be helpful in this population in order to perform a thorough examination of 
the mucosa and obtain biopsy specimens. The overall efficacy and safety profile of FMT in IBD 
patients and CDI requires further elucidation and is currently being investigated in an ongoing 
prospective study (NCT03106844). 
 
 
(2) Donor: Donor Selection and Screening 
 
Patient Directed vs Universal Stool Donors 
There are 2 main stool donor approaches: (1) patient directed donor and (2) universal donor. In 
the patient directed approach a donor is identified by the patient, typically a partner or spouse, 
friend, or sibling. Donors should be consented for the screening process. Selection and exclusion 
criteria are based on medical history and appropriate serologic and stool testing. There is 
heterogeneity in recommended testing protocols between U.S. and European medical societies. 
30, 39 An advantage to the patient directed method is that some patients may be more 
comfortable if they know the source of the fecal material. The patient-directed approach may 
also be considered in cases where donor diet is important (eg, recipient with a history of 
anaphylaxis or anaphylactoid reactions to a food source). Drawbacks to the patient-directed 
approach include delay in treatment while sourcing, screening, and testing a donor as well as 
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significant costs incurred in screening tests.
 40
 Additionally, using a donor known to the recipient 
may also raise ethical concerns around coercion or full-disclosure on screening especially if the 
recipient is a family member. From a clinical perspective, there are no data to suggest 
advantages in safety or efficacy in the patient-directed approach.
 22
 
 
The universal donor approach uses healthy volunteers, like a blood bank, who are screened 
through a centralized process and whose stool is frozen and banked for future use. This 
approach enables economies of scale, reduced costs, convenience for patients and providers 
and reduced waiting times for scheduling FMT procedures.
 40
 The drawback is that an infection 
transmission or other safety event may impact more than one individual, although safety and 
traceability protocols may also be enhanced through centralized collection and monitoring. 
Safety aliquots may be stored and reexamined for enteropathogens should a suspected adverse 
event arise. Overall, a universal donor approach helps address the screening and logistical 
barriers that clinicians feel are most challenging in adopting FMT.
 41
  
  
 
Frozen versus Fresh Donor Material  
Historically, fresh material was assumed to be superior to frozen fecal material in treating CDI. 
However, delivering fresh stool for FMT can pose significant operational challenges, a major 
barrier to the adoption of FMT according to a physician-based survey.
 41
 Collection and 
preparation of the fresh fecal material includes dilution, homogenization and filtering to remove 
particulate material. Donor stool is usually mixed with saline solution and homogenized by 
either blending or manually stirring. The liquid slurry is then strained if necessary to remove 
particulate matter that can be easily administered (Figure 1). Fresh stool should be used to 
perform FMT on the same day it is collected, preferably within 6 hours.  
 
Previously, there was concern that freezing and thawing stool may reduce the number of viable 
microbiota, although data have emerged to suggest frozen-and-thawed and fresh donor 
material are equally effective in recurrent CDI. Hamilton and colleagues
42
 were among the first 
to report the efficacy of a standardized, frozen preparation for transplantation of fecal 
microbiota. More recently, Lee and colleagues
43
 performed a large non-inferiority trial assessing 
the efficacy of fresh versus frozen-and-thawed FMT for the management of recurrent CDI. In 
this randomized, controlled trial, 108 patients received FMT by enema with material that had 
been frozen and 111 received FMT with fresh donor material. They demonstrated clinical 
resolution of CDI, per protocol, in 83.5% of patients in the frozen-and-thawed FMT arm and 
85.1% in the fresh FMT arm, concluding that frozen material was not inferior to fresh in 
achieving clinical resolution of CDI.  
 
Stool Banks 
The logistics of stool preparation and delivery has been a barrier to providers offering FMT.
 
41
Given the operational advantages of the universal donor model and frozen material, stool 
banks have emerged to enable safe access to FMT at scale. There remains regulatory 
uncertainty regarding the role of stool banks; however, current draft FDA guidance, released for 
public comment only, does not affect the existing FDA guidance that enables clinicians to 
proceed with FMT from stool banks for patients with recurrent CDI. 44  
 
Providers in the United States (and some countries outside of the United States) may source 
screened, frozen fecal microbiota preparations from universal stool banks. OpenBiome, a 
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nonprofit stool bank based in Somerville, MA offers formulations for delivery by the lower GI 
tract, upper GI tract, and capsules for oral delivery. AdvancingBio, a nonprofit stool bank based 
in Ranchero, CA offers preparations for delivery to the lower GI tract. In addition to these public 
stool banks, several academic institutions around the country have set up in-house stool banks 
within their institutions for local use.  
 
Donor screening, GMP manufacturing, and quality assurance monitoring by universal stool 
banks: 
In addition to the standard practices outlined above, universal donors at one U.S. stool bank ( 
OpenBiome, Somerville, Mass) undergo dual laboratory testing, mandatory material 
quarantining to address a seroconversion window, standardized continuous health monitoring 
for changes in health status or risk factors and the preservation of safety aliquots for testing in 
the case of a suspected adverse event.
 45
 This robust screening program illustrates a challenge 
that individual practitioners often face when obtaining healthy stool donors, because the stool 
bank reports that only 2.8% of donors qualify to provide stool among 1387 candidates in a 
prospective study.
 46
  Donor material is processed in a Good Manufacturing Practice (GMP) 
facility and stored at -80°F until it is shipped to medical facilities overnight on dry ice with 
temperature verification. 
 
Observational data from this stool bank supports the efficacy and safety data seen in clinical 
trials in CDI. In a 2,050 patient cohort, the overall clinical cure rate from physician reported 
outcome data was 84.0% across all FMT delivery modalities including colonoscopy, upper 
endoscopy, nasogastric tube and enema.
 47
 Forty-two adverse events were reported, although 
none were determined to be definitely related to FMT, three were possibly related to the FMT 
and 39 were not related based on NIH criteria after independent safety review.
 47
  Screening and 
safety data from AdvancingBio were unavailable at the time of publication. 
 
Donor Screening 
Potential donors should be screened with a complete social history to assess for behaviors, 
which may confer increased risk for infectious disease transmission, similar to screening 
methods used for blood donation. Prospective donors should be healthy adults without any 
gastrointestinal pathology and who have not taken antibiotics within the previous 3 months. 
Additionally, donors should be excluded if they have a history of diseases that may be 
associated with alterations in the gut microbiome, including autoimmune or atopic illnesses, 
chronic pain syndromes (fibromyalgia, chronic fatigue), neurologic or neurodevelopmental 
disorders, certain neuropsychiatric conditions, metabolic syndrome, obesity (body mass index 
>30), moderate-to-severe malnutrition, malignant illnesses, or ongoing oncologic therapy. 
 28
 
 
Those who meet initial eligibility should then undergo serologic and stool testing to screen for 
infectious pathogens. At a minimum, donors should have serological testing for HIV (EIA), 
Hepatitis A (HAV IgM), Hepatitis B (HBsAg) and Hepatitis C (anti-HCV Ab), and syphilis (FTA-ABS) 
and stool testing should include screening for common enteric pathogens, C difficile toxin B, and 
examination for ova and parasites.
 42
 Some protocols recommend testing donor stool for viruses 
(adenovirus, norovirus, rotovirus) and antibiotic resistant bacteria such as vancomycin resistant 
enterococcus (VRE), extended spectrum beta-lactamase (ESBL) producing organisms and 
carbapenem-resistant enterobacteriaceae (CRE). Practically, it is important to discuss testing 
with the local microbiology laboratory before screening to ensure formed donor stool won’t be 
discarded in error.  
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Additional testing should be considered when the recipient is immunocompromised. 
Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) pose a particular dilemma for clinicians. 
Given the high rates of carriage for both EBV and CMV in a healthy, adult population, 
excluding EBV or CMV positive donors would make it prohibitively difficult to identify suitable 
donors to provide access to care.
 48
Unless the donor has been screened for CMV and EBV, FMT 
material should be treated as presumptively CMV and EBV positive and not used in severely 
immunocompromised patients who are seronegative (IgG) for CMV or EBV. If FMT must be 
performed in severely immunocompromised patients at risk for CMV or EBV-associated 
diseases, there are two potential approaches. First, assess the recipient for CMV and EBV, and, if 
negative, FMT material with unknown donor CMV or EBV status (presumed positive) may be 
considered after extensive discussion of the risks, benefits, and alternatives including no 
treatment in the informed consent process. Second, the use of a directed donor with matching 
serology may be considered.  
 
It should be noted that there have been no reported cases of EBV transmission from a universal 
donor. There have been two published cases of CMV post-FMT. The first occurred in the context 
of a randomized controlled trial of FMT for ulcerative colitis with CMV sero-conversion at 7 
weeks post-FMT.
 49
However, this patient was in the control arm and had received their own 
fecal material in an autologous FMT. No patient's in the treatment arm receiving donor material 
acquired CMV. In a second published case, a patient with ulcerative colitis developed CMV 
colitis after performing FMT at home using donor material from han unscreened infant. 
 50
It is 
important to note, that patients with IBD may develop colitis from CMV reactivation; thus, 
causality remains unclear. 
 
 
(3) Discussion: Discuss the risks, benefits and alternatives to FMT (informed consent) 
 
Informed Consent 
Given the paucity of long-term safety data for FMT, it is critical to conduct and document a 
thorough informed consent discussion with the patient. This discussion should cover the risks 
and benefits of FMT material and the delivery modality as well as any alternative treatment 
options.  
 
Risks 
There have been no serious adverse events definitively attributed to FMT material in the peer-
reviewed literature.
 23, 51
 Nevertheless, the patient should be informed of common mild adverse 
reactions potentially related to FMT including transient diarrhea, abdominal cramps/discomfort 
and nausea, fever, bloating, belching, vomiting, borborygmus, constipation, and excess 
flatulence. There have not been any definitely related serious adverse events attributable to 
FMT material. However, the following potential serious adverse events should be 
communicated to the patient:  
 
(1) Infection: Although material should have been screened for common enteric pathogens, 
there is a risk of transmission of known and unknown infectious organisms contained in the 
donor stool. Post-FMT bacteremia (eg, E coli, K pneumoniae), sepsis and fatal events may occur. 
Cases reported in the literature include bacteremia, cytomegalovirus colitis, pyrexia of unknown 
origin, influenza B transmission, and non-CDI diarrhea (eg, norovirus). 38, 52, 53 A multicenter 
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retrospective study of immunocompromised patients receiving FMT to treat CDI did not report 
any infectious adverse events in this “high risk” cohort.
 38 
We strongly recommend that patients 
who are immunosuppressed and at particularly high risk of CMV or EBV infection should be 
counseled about the potential for additional risks for opportunistic and viral infections. 
 
(2) Gastrointestinal: Abdominal pain, appendicitis, peritonitis and diverticulitis have been 
reported as possibly related to FMT in cases reported in the peer reviewed literature.
 38, 54-
57
There is a theoretical risk of small intestinal bacterial overgrowth when FMT is delivered into 
the upper GI tract, however there have been no reported cases to date.
 58
 
 
(3) Allergy/Anaphylaxis to antigens in donor stool: Whilst no cases of allergy or anaphylaxis 
have been reported in the literature, patients should be screened for food allergies before FMT.  
If the patient reports a severe food allergy, either the patient should be evaluated by an allergist 
to confirm the allergy if there is there is any question or if confirmed the stool source should be 
a directed donor, who has abstained from the offending agent for a period of 7 days.  
 
(4) Autoimmune: Rheumatoid arthritis, Sjogren syndrome, peripheral neuropathy, and 
idiopathic thrombocytopenic purpura have all been reported in the peer reviewed literature as 
possibly related to FMT.
 59
 
 
(5) Non-infectious disease transmission: There is a theoretical risk of developing disease that 
may be related to donor gut microbiota. These include obesity, metabolic syndrome, neurologic 
disorders, psychiatric conditions and malignancy. Persons with these known conditions should 
be excluded from donating stool, although a theoretical risk of acquiring these conditions and 
other unknown microbiome-mediated diseases after FMT remains. 
 
(6) Inflammatory bowel disease (IBD) flare: In those with underlying IBD, flares have been 
reported in up to 15% of cases especially when there is active background disease at the time of 
FMT
 60
, although these were uncontrolled studies and potentially driven by oversensitive C 
difficile PCR testing, as the risk appears lower in randomized controlled trials.
 49, 61-63
 
 
(7) Treatment failure or improvement but incomplete resolution of symptoms: FMT has been 
successful in controlled trials, but there is potential for treatment failure or incomplete 
resolution of patient’s symptoms. Patient expectations should be calibrated appropriately 
during the discussion. Predictors of treatment failure include severe and severe-complicated 
CDI, inpatient status during FMT, and the number of previous CDI-related hospitalizations
 64
 as 
well as underlying IBD.
 60
 
 
Procedure-related risks 
The chosen delivery modality carries risks independent of FMT material. There have been 2 
serious adverse events reported in the peer-reviewed literature determined to be definitely 
related to FMT procedure. These include aspiration after upper delivery of FMT and bowel 
perforation after colonoscopic delivery of FMT. 65, 66Importantly, these adverse events were 
related to the FMT procedure and adverse events associated with the delivery modality. Risks 
related to the FMT procedure should be clearly discussed with the patient and the choice of 
delivery modality may depend on the patient or specific clinical situation.  
 
Pre-FMT Patient Education 
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Patients should be given clear advice on how to clean their home bathroom and high touch 
surfaces before FMT to prevent ongoing exposure to spores and CDI reinfection.  
 
Specifically, patients should be advised that traditional household cleaning products are not 
sufficient and they should use an Environmental Protection Agency (EPA)-registered disinfectant 
with a C difficile-sporicidal label claim.
 67
 These agents can be any chlorine-containing cleaning 
agents at a concentration of at least 5,000 ppm, eg, household bleach (diluted with one parts 
bleach to 10 parts water). Patients should take precautions in cleaning high touch surfaces, 
cleaning surfaces with at least 10 minutes of contact between a surface and disinfectant. If the 
patient lives in an assisted living residence, they should speak the director of their facility to 
ensure that the appropriate measures are taken to disinfect their living environment. 
 
Finally, patients should be advised to discontinue antibiotics before FMT. Anecdotal experience 
suggests discontinuing anti-CDI therapy 2 days before FMT, although the literature reports 
between 1 and 3 days.
 18, 22, 59
 
 
(4) Delivery: Selecting the delivery modality to administer FMT 
 
Routes of administration include the lower GI tract (with instillation into the right side of the 
colon or TI via colonoscopy or instillation into the distal colon via enema or flexible 
sigmoidoscopy) or the upper GI tract (via upper endoscopy, nasoenteric tubes, or capsules). 
Although there is no well-powered head-to-head study on FMT delivery modality, a pilot study
 19
 
(n=20) suggests colonoscopic delivery appears to be a more effective modality then upper GI 
delivery. A systematic review and meta-analysis conducted by Kassam and colleagues
22
 
demonstrated that the combined efficacy rates of lower GI delivery, driven by colonoscopy, was 
consistently higher than combined efficacy rates of upper GI delivery (91.4% versus 82.3% 
respectively).
 
However, there are advantages and disadvantages to each route of FMT delivery, 
which should be considered on a case-by-case basis.  
 
Lower GI Tract Administration 
Lower GI routes of administration include enema, sigmoidoscopy or colonoscopy. Combined 
efficacy rates for lower GI administration including enema, sigmoidoscopy, and full colonoscopy 
has been reported to range from 84% to 93%.
 22
 
 
Retention Enema 
Retention enema is inexpensive and generally well tolerated. The benefit of this method is it 
does not require sedation and therefore has little procedural risk. Furthermore, it can be 
administered by a non-physician. The enema method is often used in pediatrics or patients with 
colostomies. The study by Zipursky and colleagues,
68
 which solicited patients perceptions and 
willingness to consider FMT treatment, found that patients preferred the enema route of 
delivery over upper GI delivery.
 
The drawbacks to FMT by enema include that patients may have 
difficulty retaining the material due to poor rectal sphincter tone. In addition, the efficacy rates 
with enema administration for the treatment of CDI is the lowest of all FMT modalities. Lee and 
colleagues69 demonstrated a 47.9% cure rate after a single enema administration in participants 
with recurrent CDI. However, the cumulative clinical cure rate improved to 86.2% with repeated 
enemas, with some participants requiring up to 6 enemas.  
 
Lower endoscopy 
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These routes of administration, which include both colonoscopy and sigmoidoscopy, are well 
tolerated. They do carry procedural related risk, but they additionally carry the benefit of 
examination of the colonic mucosa and biopsy if necessary to ensure there are no competing 
diagnoses. 
 
Sigmoidoscopy: 
Recto-sigmoidoscopy may be the preferred route of delivery based on patient’s choice or in 
patients who are frail or at a high risk of intestinal perforation (severe colitis or significant 
colonic distention). Several experts have advised less invasive modalities such sigmoidoscopy in 
high risk patients.
 70, 71
 To date, there are no studies directly comparing the efficacy of 
sigmoidoscopy to other delivery modalities, including full colonoscopy, for the treatment of CDI.  
 
Colonoscopy 
Colonoscopy remains the most common FMT delivery modality and is supported by a placebo-
controlled trail and an abundance of observational data supporting its efficacy in recurrent CDI.
 
21, 22
It is particularly useful in patients with IBD, as it enables assessment of disease activity at the 
time of FMT. If may also be appropriate in younger patients, in whom recurrent CDI may herald 
a new diagnosis of IBD. This route does carry additional costs and requires technical expertise 
although a cost-effectiveness analysis showed that FMT by colonoscopy was less costly 
compared with vancomycin for both recurrent CDI and initial CDI.
 72, 73
Additionally, 
administration to the right side of the colon appears to have high overall efficacy with up to a 
93% clinical cure rate after a single dose.
 16
 
 
Upper GI Tract Administration 
Efficacy rates with upper administration have been reported to be 81% to 86%.
 22
 It is important 
to note that for pre-pyloric upper GI administration a proton pump inhibitor (PPI) should be 
administered 48 hours before infusion. 
 
Nasoenteric tube 
This delivery method appears to be more routinely used in Europe than the United States, 
potentially because a Dutch group conducted the first randomized controlled trial using 
nasoduodenal infusion of FMT
 18
. The benefit to this method is that it does not require sedation, 
however it may be uncomfortable, and studies investigating patients’ perceptions regarding 
nasoenteric administration have demonstrated that patients perceive this route of delivery as 
the least appealing.
 68
 Additionally, this route of delivery requires radiological confirmation of 
tube placement and there is some risk of vomiting and aspiration.
 66
A study conducted by van 
Beurden and colleagues
74
 using the duodenal route reported a significant number of 
participants who experienced regurgitation (13%) and one death due to pneumonia in which a 
causal relation to the FMT could not be excluded. The inherent risks associated with upper GI 
delivery should be carefully considered, particularly in patients with severe acute C difficile 
colitis and/or ileus. We caution against delivery of a large stool dose to the upper GI tract to 
reduce the risk of regurgitation of fecal material.   
   
Upper Endoscopy  
This route carries the same risk and has the same efficacy rate as nasoenteric tube 
administration. 22However, this method requires sedation and carries additional procedural 
risks. This option can be considered in patients who have had complicated lower GI surgery and 
those without intact colons. Some physicians may prefer upper endoscopy because of concerns 
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around performing a colonoscopy when the colon is severely inflamed. However, it is important 
to note that patients undergoing FMT for recurrent CDI are typically treated with a course of 
vancomycin to control the acute infection preprocedure and rarely have inflamed colons at the 
time of FMT administration.  
 
Capsules 
More recently, studies have begun using FMT capsules as a route of delivery, recognizing that 
there are circumstances when it may be inappropriate, contraindicated, or contrary to patient 
preferences to deliver material via traditional routes of administration for CDI. In terms of 
patient perceptions, Zipursky and colleagues
68
 report that more aesthetically appealing FMT 
formulations, such as capsules, would both eliminate potential barriers to treatment and reduce 
the necessity for healthcare resources and procedure time for clinicians.
 
 
  
Although the optimal dose is still under investigation, there have been several proof-of-concept 
studies that have shown equivalent efficacy rates. Youngster and colleagues
75
 reported their 
experience with a capsule formulation that averaged 1.6 grams of stool per capsule in which 
they dosed 15 capsules on 2 consecutive days. They reported a 70% cure rate after an initial 
dose in a cohort of 140 patients. Those that failed to achieve cure were re-treated, bringing the 
cumulative cure rate up to 90%. There were several adverse events deemed to be related or 
possibly related to the FMT including fever, hospitalization due to relapse of CDI and one de 
novo diagnosis of ulcerative colitis.
 76
 Similarly, Hirsch and colleagues
77
 demonstrated a clinical 
cure rate of 68% in the 19 participants, using capsules containing purified, concentrated, and 
cryopreserved fecal bacteria and this increased to 89% with retreatment. 
 
Allegretti and colleagues
78
 conducted the first dose-finding study for FMT capsules (0.75 grams 
of stool per capsule with upper GI release) assessing 30 capsules once (low dose) versus 30 
capsules on 2 consecutive days (high dose). Efficacy rates between the groups were similar on 
initial dose (70%) and there were no adverse events reported. Overall, FMT capsules show great 
promise but may benefit from delayed-release formulations, to mimic the delivery approach of 
colonoscopic FMT. 
 
Other considerations 
 
Bowel Preparation:  
It is unclear if bowel preparation is needed regardless of delivery modality. Previous studies 
have used bowel lavage when administering the FMT by upper GI route.
 18, 74
It has been 
speculated that bowel prep flushes the bowel of residual C difficile spores and antibiotics and 
prepares the gut for engraftment of donor material.
 18
Microbial sequencing studies suggest that 
the intestinal microbiota rapidly returns to baseline after the administration of varying doses 
and types of bowel preparation.
 79, 80
Certainly, bowel preparation is recommended for lower 
endoscopy, primarily for visualization. The exception to this is patients with severe complicated 
disease, in whom an ileus is often present. 
 
Timing of FMT:  
FMT is generally performed as an outpatient procedure in stable patients with recurrent CDI. 
FMT should be performed once patients have responded to anti-CDI antibiotics for a minimum 
of 4 days 18. Inpatient FMTs are generally reserved for patients with severe and severe- 
complicated CDI. Additionally, inpatients are more likely to experience FMT failure as 
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demonstrated by Fischer et al
 64
. In a 462-patient cohort, 52% of the 94 inpatients experienced 
FMT failure at 1 month compared with 10% of the 368 outpatients who experienced FMT failure 
at 1 month. This highlights the complexity of the inpatient population.  
  
(5) Discharge: Patient discharge and follow-up after FMT 
 
Immediately after FMT, patients should retain the slurry for 45 minutes to an hour if possible. In 
cases of endoscopic administration, patients are kept supine in the recovery area of the 
endoscopy unit and encouraged to retain the material until just before discharge.  Loperimide 
pre-procedure may aid in retention. Vancomycin should not be resumed routinely post-
procedure. Patients should be counseled on antibiotic stewardship practices including the 
avoidance of unnecessary antibiotics, and patients and providers should be very cautious about 
initiating antibiotics in these patients, specifically if no infection is identified (eg, asymptomatic 
bacteruria, before dental cleanings in patients with prosthetic joints). Patients should be 
empowered to advocate for themselves to ensure antibiotics are truly necessary before they are 
administered. 
 
If patients do require non-CDI antibiotics in the future they should be reassured that the 
recurrence rates after a successful FMT are low. Fischer and colleagues report that out of 152 
patients, the overall long-term CDI recurrence rate was 10.5% after a successful FMT. Of those 
who experienced a recurrence, 63% had received antibiotics. Prophylactic probiotics or 
concomitant anti-CDI antibiotics were not found to prevent recurrence. Therefore, we do not 
recommend the use of prophylactic anti-CDI therapy in the setting of non-CDI antibiotic use post 
FMT.
 81
 
 
Patients should be followed closely to monitor for CDI recurrence for up to 8 weeks after FMT. 
Although there are variations on this, a possible follow-up plan would include a phone call to the 
patient between 72 hours and 1 week post FMT and a follow-up visit in the clinic at 8 weeks. 
Importantly, physicians need to be aware that post-infectious IBS can occur in up to 30% of 
patients after CDI.
 82
 Repeat testing, preferably with the two step-testing method previously 
discussed, should only be conducted in the event of recurrent diarrhea. A pragmatic approach to 
diarrhea post-FMT is outlined in Figure 2. Stool should not be tested unless patients are 
experiencing 3 or more unformed stools per day for 2 or more days or there are other systemic 
symptoms suggestive of severe CDI.  
 
If patients have not experienced a recurrence by 8 weeks after FMT, they can be considered 
clinically cured. C difficile testing for cure after FMT in asymptomatic patients is not 
recommended. This practice has evolved from existing C difficile treatment guidelines that do 
not recommend testing for cure in asymptomatic patients. The basis for this recommendation is 
that stool C difficile PCR can remain positive for up to 30 days after successful treatment with 
antibiotics.
 10
 
In conclusion, the emergence of FMT has transformed the treatment landscape of C difficile 
infection. Given its rapid adoption, the paucity of long-term safety data and ongoing 
uncertainties in the microbiome space, clinicians must be thoughtful and systematic in treating 
patients.  This 5 D approach is a useful primer for developing an FMT protocol, from patient 
selection through follow-up.    
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Table 1: 5D framework for fecal microbiota transplantation to treat Clostridium difficile infection  
 
Decision Donor Discussion Delivery  Discharge  
 
Clinicians should 
decide if a CDI 
patient is 
appropriate for 
FMT.  
Clinicians should 
review the CDI 
indication, CDI 
tests and 
potential 
exclusion 
factors. 
Clinicians should 
consider 
alternative 
diagnoses, such 
as post-
infectious IBS or 
IBD, particularly  
in patients with 
atypical 
presentations.  
 
 
Clinicians should 
select the donor 
model: patient 
directed or 
universal donor 
from a stool 
bank  
Robust donor 
testing should be 
completed in 
keeping with 
best practices. 
 
Clinicians should 
have a discussion 
with their 
patient regarding 
the risks, 
benefits and 
alternatives of 
FMT (informed 
consent) 
including no 
treatment. 
 
Clinicians should 
select the ideal 
FMT delivery 
modality for the 
patient 
depending on 
the clinical 
context. 
 
Upon discharge, 
clinicians should 
council patients 
on cleaning high-
touch surface 
areas and 
antibiotic 
stewardship 
practices.  
Clinicians should 
initiate follow-up 
to assess for 
adverse events 
and recurrence 
of CDI. 
 
 
 
 
Figure 1: Stool processing for FMT with fresh donor stool.  
 
 
Figure 2. Post FMT testing algorithm for patients with diarrhea.  
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